Theratechnologies Inc. (T:TH)

Business Focus: Biopharmaceuticals

Get the company report for the most recent outlook updated daily

Apr 15, 2024 04:15 pm ET

Theratechnologies Announces Mailing of Management Proxy Circular in Connection with its Annual Meeting of Shareholders

Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that the Company has mailed its 2024...

Apr 11, 2024 07:30 am ET

Theratechnologies to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference

Apr 10, 2024 07:30 am ET

Theratechnologies Reports Financial Results and Provides Business Update for First Quarter 2024

Apr 08, 2024 04:30 pm ET

Theratechnologies Preclinical Data Presentation at AACR 2024 Highlights Versatility and Flexibility of SORT1+ Technology™ Oncology Platform

Apr 05, 2024 11:00 am ET

Theratechnologies Appoints Elina Tea to its Board of Directors

Apr 03, 2024 07:30 am ET

Theratechnologies to Announce First Quarter 2024 Financial Results and Provide Business Update

Mar 28, 2024 07:30 am ET

Theratechnologies to Present Preclinical Data at AACR on Multiple PDCs Showcasing Potential of SORT1+Technology™ Platform

Mar 22, 2024 09:36 am ET

Theratechnologies Announces Update on its Preclinical Oncology Research Program

Mar 21, 2024 08:00 pm ET

Theratechnologies Appoints Jordan Zwick to its Board of Directors

Mar 21, 2024 07:30 am ET

Theratechnologies Initiates Increased Dose Level in Phase 1 Clinical Trial of Sudocetaxel Zendusortide in Advanced Ovarian Cancer

Feb 29, 2024 04:34 pm ET

Theratechnologies Announces the Resignation of One of Its Directors, Mr. Alain Trudeau

Feb 27, 2024 07:30 am ET

Theratechnologies Receives Refusal to File Letter for Trogarzo® Intramuscular Method of Administration sBLA from FDA

Feb 21, 2024 07:30 am ET

Theratechnologies Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2023 and Provides 2024 Guidance

Feb 20, 2024 07:30 am ET

Theratechnologies Announces Publication in Frontiers in Immunology that Deepens Understanding of Sudocetaxel Zendusortide (TH1902) Molecular Mechanism of Action

Feb 15, 2024 07:30 am ET

Theratechnologies Completes Enrollment of First Six Patients in Updated Phase 1 Clinical Trial of Sudocetaxel Zendusortide in Advanced Ovarian Cancer

Feb 06, 2024 07:30 am ET

Theratechnologies to Announce Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update

Jan 24, 2024 07:00 am ET

Theratechnologies Receives Complete Response Letter (CRL) from the FDA for the F8 Formulation of Tesamorelin sBLA

Jan 23, 2024 07:30 am ET

Theratechnologies Receives Update from FDA on Tesamorelin F8 Supplemental Biologic License Application

Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, has received correspondence from the U.S. Food and Drug...

Jan 02, 2024 07:30 am ET

Theratechnologies Submits sBLA for Trogarzo® Intramuscular (IM) Method of Administration to FDA

Dec 21, 2023 03:09 pm ET

Theratechnologies Announces Renewal of Shelf Prospectus and Filing of Registration Statement

MONTREAL, Dec. 21, 2023 /CNW/ - Theratechnologies Inc. ("Theratechnologies" or the "Company") (Nasdaq: THTX) (TSX: TH), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it has filed a preliminary short form base shelf prospectus with the securities regulatory authorities of all the provinces of Canada and a corresponding shelf registration statement with the United States Securities and Exchange Commission (the "SEC") on Form F-3.

Dec 21, 2023 03:09 pm ET

Theratechnologies Announces Renewal of Shelf Prospectus and Filing of Registration Statement

MONTREAL, Dec. 21, 2023 /PRNewswire/ - Theratechnologies Inc. ("Theratechnologies" or the "Company") (Nasdaq: THTX) (TSX: TH), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it has filed a preliminary short form base shelf prospectus with the securities regulatory authorities of all the provinces of Canada and a corresponding shelf registration statement with the United States Securities and Exchange Commission (the "SEC") on Form F-3.

Dec 13, 2023 07:30 am ET

Theratechnologies Announces FDA Approval of Trogarzo® 90-Second Intravenous (IV) Push Loading Dose

Nov 24, 2023 07:30 am ET

Theratechnologies Receives 2023 CQDM ADRIQ RSRI Innovation Award

Oct 31, 2023 12:34 pm ET

Theratechnologies Announces Closing of US$25 Million Public Offering of Common Shares and Concurrent Private Placement

Theratechnologies Inc. (“Theratechnologies” or the “Company”) (Nasdaq: THTX; TSX: TH), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it has closed its previously announced...

Oct 26, 2023 08:00 am ET

Theratechnologies Announces Pricing of US$25 Million Public Offering of Common Shares and Concurrent Private Placement

Oct 25, 2023 04:13 pm ET

Theratechnologies Announces Proposed Public Offering of Common Shares and Concurrent Private Placement

Oct 24, 2023 07:00 am ET

Theratechnologies Announces Operational Update

Oct 19, 2023 07:30 am ET

Theratechnologies’ Ibalizumab Demonstrates Cost-Effectiveness as an Addition to Routine Clinical Care in Heavily Treatment-Experienced People with HIV

Oct 16, 2023 07:30 am ET

Theratechnologies Announces Finalization of Amendments to Some of the Terms and Conditions of its Credit Agreement with Marathon

Oct 13, 2023 07:30 am ET

Theratechnologies Presents Data at ID Week Showing Tesamorelin Reduces Visceral Adipose Tissue (VAT) and Liver Fat in People with HIV on Integrase Inhibitors (INSTIs)

Oct 13, 2023 07:00 am ET

Theratechnologies Announces Results from Trogarzo® (Ibalizumab-uiyk) Intramuscular Administration Study

Oct 12, 2023 07:30 am ET

Theratechnologies Announces Dosing of First Patient in Updated Clinical Trial of Sudocetaxel Zendusortide in Advanced Ovarian Cancer

Oct 04, 2023 07:30 am ET

Theratechnologies Receives January 2024 PDUFA Goal Date for Tesamorelin F8 Formulation sBLA

Sep 26, 2023 07:30 am ET

Theratechnologies Reports Financial Results for the Third Quarter and Nine Months of Fiscal 2023 and Provides Business Updates

Sep 25, 2023 07:30 am ET

Theratechnologies Announces Agreement in Principle with Marathon to Amend Some of the Terms and Conditions of its Loan Facility

Sep 25, 2023 07:00 am ET

Theratechnologies Submits Tesamorelin F8 Formulation sBLA for FDA Review

Sep 20, 2023 07:00 am ET

Theratechnologies to Present at the Cantor Fitzgerald Global Healthcare Conference 2023

Sep 18, 2023 04:15 pm ET

Theratechnologies to Announce Third Quarter 2023 Financial Results and Provide Business Update

Sep 07, 2023 01:57 pm ET

Theratechnologies to Present at the H.C. Wainwright 25th Annual Global Investment Conference

Sep 05, 2023 07:00 am ET

Theratechnologies Announces Certain Preliminary Q3 2023 Financial Highlights

Aug 30, 2023 10:34 am ET

Theratechnologies Announces All U.S. Oncology Clinical Sites Now Enrolling for Phase 1 Trial of Sudocetaxel Zendusortide

Aug 21, 2023 03:24 pm ET

Toronto Stock Exchange, Theratechnologies Inc., View From The C-Suite

TORONTO, Aug. 21, 2023 /CNW/ - Paul Lévesque, President and Chief Executive Officer, Hamilton Thorne Ltd. ("Theratechnologies", the "Company", or "we") (TSX: TH) shares his Company's story in an interview with TMX Group.

Jul 31, 2023 07:00 am ET

Theratechnologies Completes 1-for-4 Reverse Stock Split

Theratechnologies Inc. (“Theratechnologies”, the “Company”, or “we”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it has completed the...

Jul 28, 2023 04:44 pm ET

Theratechnologies Announces Amendments to its Term Loan Facility With Affiliates of Marathon Asset Management

Jul 21, 2023 07:00 am ET

Theratechnologies Announces the Resignation of One of Its Directors, Mr. Gary Littlejohn

Jul 20, 2023 07:00 am ET

Theratechnologies Announces 1-for-4 Reverse Stock Split

Jul 12, 2023 07:30 am ET

Theratechnologies Reports Second Quarter 2023 Financial Results and Business Updates

Jun 30, 2023 08:09 am ET

Canadian Investment Regulatory Organization Trading Halt - TH.DB.U

TORONTO, June 30, 2023 /CNW/ - The following issues have been halted by CIRO:

Jun 29, 2023 07:30 am ET

Theratechnologies to Announce Second Quarter 2023 Financial Results and Provide Business Update

Jun 22, 2023 07:30 am ET

Theratechnologies Draws Down on US$20 Million Second Tranche Under its Term Loan Facility With Affiliates of Marathon Asset Management

Jun 12, 2023 07:30 am ET

Theratechnologies June 13 Oncology Investigator Call to Update Investors & Analysts on Phase 1 Sudocetaxel Zendusortide Trial

Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, will hold a video conference call on Tuesday, June 13,...

Jun 02, 2023 12:15 pm ET

Theratechnologies Receives FDA Agreement to Amended Trial Protocol for its Lead PDC Candidate Sudocetaxel Zendusortide

May 25, 2023 05:31 pm ET

Theratechnologies to Present Preliminary Safety and Efficacy Data from Phase 1 Trial of Sudocetaxel Zendusortide in Heavily Pretreated Cancer Patients at ASCO 2023

May 19, 2023 05:11 pm ET

Early Warning Report Issued Pursuant to National Instrument 62-103 - Acquisition of Securities of Theratechnologies Inc.

/NOT FOR DISTRIBUTION TO UNITED STATES OF AMERICA WIRE SERVICES OR DISSEMINATION IN THE UNITED STATES OF AMERICA/

May 09, 2023 12:01 pm ET

Theratechnologies Reports on its Annual Meeting of Shareholders

Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, reported the voting results from its annual meeting of...

May 04, 2023 07:30 am ET

Theratechnologies’ Trogarzo® (Ibalizumab-uiyk) Shortens Time to HIV Undetectability and Extends Durability of Undetectability and Viral Suppression in a Matched Treatment Comparison

Apr 18, 2023 09:00 am ET

Theratechnologies Data Presentations at AACR 2023 Showcase Potential of Sudocetaxel Zendusortide as a Single Agent and in Combination with other Anticancer Therapies

Apr 18, 2023 07:30 am ET

Theratechnologies to Present at the 2023 Bloom Burton & Co. Healthcare Investor Conference

Montreal, Quebec--(Newsfile Corp. - April 18, 2023) - Theratechnologies (NASDAQ: THTX) (TSX: TH), a biopharmaceutical company focused on the development and commercialization of innovative therapies, will be participating in the 2023 Bloom Burton & Co. Healthcare Investor Conference, which will take place on April 25 and 26 at the Metro Toronto Convention Centre.

Apr 12, 2023 07:30 am ET

Theratechnologies Reports Financial Results and Business Updates for First Quarter 2023

Apr 03, 2023 07:30 am ET

Theratechnologies to Announce First Quarter 2023 Financial Results and Provide Business Update

Theratechnologies Inc. (TSX: TH) (NASDAQ: THTX) (“Theratechnologies”), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it will report financial results for its first quarter...

Mar 14, 2023 06:42 pm ET

Theratechnologies to Present Preclinical Data at AACR Demonstrating Synergy Between TH1902 and Anti-PD-L1 Immunotherapy in Cold Tumor Model

Mar 07, 2023 06:00 am ET

Theratechnologies Receives Nasdaq Notification Letter Regarding Share Price

Feb 28, 2023 07:30 am ET

Theratechnologies Reports Financial Results and Business Updates for the Fourth Quarter and Full Year Fiscal 2022

Feb 28, 2023 06:30 am ET

Theratechnologies Announces Amendment to its Term Loan Facility With Affiliates of Marathon Asset Management

Feb 22, 2023 05:30 pm ET

Theratechnologies Presents New Tesamorelin Data Demonstrating Improvement of Metabolic Syndrome in People with HIV

Feb 16, 2023 07:30 am ET

Theratechnologies Announces Path to Resume TH1902 Clinical Development

Feb 14, 2023 05:00 pm ET

Theratechnologies to Announce Fourth Quarter and Full Year 2022 Financial Results and Provide Business Update

Jan 04, 2023 07:45 am ET

Open Letter to Shareholders from CEO Paul Levesque

Dec 01, 2022 06:30 pm ET

Theratechnologies Announces Update from Ongoing TH1902 Study

Oct 26, 2022 07:30 am ET

Theratechnologies Reports Data Showing High Expression of Sortilin (SORT1) in Multiple Solid Tumors from Tissue Microarrays

Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies reports data from a tissue microarrays (TMAs) study...

Oct 13, 2022 07:30 am ET

Theratechnologies Reports Financial Results for the Third Quarter of Fiscal 2022 and Provides Business Update

Oct 12, 2022 07:30 am ET

Theratechnologies Presents Data Demonstrating High Expression of Sortilin (SORT1) in Multiple Tumor Types at 34th EORTC-NCI-AACR Symposium

Oct 03, 2022 03:09 pm ET

Theratechnologies’ Trogarzo® Approved by FDA for 30-Second Intravenous (IV) Push, Simplifying HIV Treatment for Heavily Treatment-Experienced Population

Sep 26, 2022 07:30 am ET

Theratechnologies to Announce Third Quarter 2022 Financial Results and Provide Business Update

Theratechnologies Inc. (TSX: TH) (NASDAQ: THTX) (Theratechnologies), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it will report financial results for its third quarter...

Sep 19, 2022 04:15 pm ET

Theratechnologies to Present at the Cantor Oncology, Hematology & HemeOnc Conference

Sep 12, 2022 07:30 am ET

Theratechnologies TH1902 Study Published in Pharmaceutics Demonstrates Inhibition of Human Sortilin (SORT1)-Positive Ovarian and Triple-Negative Breast Cancer Stem-Like Cells and Tumor Growth

Aug 02, 2022 07:30 am ET

Theratechnologies to Present at the Canaccord Genuity 42nd Annual Growth Conference

Jul 28, 2022 11:19 am ET

Theratechnologies Trogarzo® Data at AIDS 2022 Shows Potential for Improved Treatment Regimens

Jul 27, 2022 06:47 pm ET

Theratechnologies Announces Closing of Funding of $40 Million Under the Terms of its Credit Agreement

Jul 14, 2022 07:30 am ET

Theratechnologies Reports Second Quarter and First Half Fiscal 2022 Financial Results and Provides Business Update

Theratechnologies Inc. (Theratechnologies, or the Company) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today reported business highlights and financial results for...

Jul 14, 2022 06:30 am ET

Theratechnologies Provides Update on the Dose Escalation Portion of Fast Track Designated TH1902 First-in-Human Study in Advanced Resistant Malignancies

Theratechnologies Inc. (“Theratechnologies” or “the Company”) (TSX:TH) (NASDAQ:THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today provided an update on the dose escalation portion of...

Jul 13, 2022 07:40 am ET

Theratechnologies Announces Binding Commitment for a Non-Dilutive Term Loan of up to $100 million from Marathon Asset Management

Theratechnologies Inc. (“Theratechnologies” or “the Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it has received a binding commitment...

Jul 12, 2022 07:30 am ET

CQDM, the Quebec Breast Cancer Foundation and Theratechnologies fund close to $2 million for research project to validate the anti-metastatic potential of TH1902 at the Université du Québec à Montréal

CQDM, the Quebec Breast Cancer Foundation and Theratechnologies today announced close to CAN $2 million of funding for a collaborative research project that aims to demonstrate the efficacy and safety of a potential innovative treatment for...

Jul 07, 2022 07:30 am ET

Theratechnologies to Announce Second Quarter 2022 Financial Results and Provide Business Update

Theratechnologies Inc. (TSX: TH) (NASDAQ: THTX) (Theratechnologies), a biopharmaceutical company focused on the development and commercialization of innovative therapies, announced today that it will report financial results for its second quarter...

May 31, 2022 07:32 am ET

Theratechnologies Announces New Head of Investor Relations

Theratechnologies Inc. (“Theratechnologies” or “the Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that Elif McDonald has joined the team as...

May 10, 2022 10:47 am ET

Appointments in Conjunction With Theratechnologies Annual Meeting

Theratechnologies Inc. (“Theratechnologies” or “the Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today held its annual meeting of shareholders. As part of...

May 10, 2022 07:30 am ET

Theratechnologies Initiates Basket Portion of TH1902 First-in-Human Study in Advanced Resistant Malignancies

Theratechnologies Inc. (“Theratechnologies” or “the Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today initiated enrollment of patients in the basket...

Apr 27, 2022 07:30 am ET

Theratechnologies to Focus Its Commercialization Activities on the North American Territory

Theratechnologies Inc. (Theratechnologies or Company) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it will focus its commercialization...

Apr 27, 2022 07:30 am ET

THERATECHNOLOGIES TO FOCUS ITS COMMERCIALIZATION ACTIVITIES ON THE NORTH AMERICAN TERRITORY

MONTREAL, April 27, 2022 /CNW Telbec/ - Theratechnologies Inc. (Theratechnologies or Company) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it will focus its commercialization activities on the North American territory only and, as a result, will cease its Trogarzo® commercialization operations in Europe. The Company has sent a notice of termination to TaiMed Biologics Inc. (TaiMed) as per our contractual obligations and will return the European commercialization rights to Trogarzo® for Tai

Apr 27, 2022 07:30 am ET

THERATECHNOLOGIES TO FOCUS ITS COMMERCIALIZATION ACTIVITIES ON THE NORTH AMERICAN TERRITORY

MONTREAL, April 27, 2022 /PRNewswire/ - Theratechnologies Inc. (Theratechnologies or Company) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it will focus its commercialization activities on the North American territory only and, as a result, will cease its Trogarzo® commercialization operations in Europe. The Company has sent a notice of termination to TaiMed Biologics Inc. (TaiMed) as per our contractual obligations and will return the European commercialization rights to Trogarzo® for Tai

Apr 25, 2022 04:16 pm ET

Theratechnologies to Present at Bloom Burton & Co. Healthcare Investor Conference 2022

Theratechnologies Inc. (“Theratechnologies” or “the Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced the Company’s participation in Bloom...

Apr 13, 2022 07:30 am ET

Theratechnologies Reports Financial Results for First Quarter Fiscal 2022 and Provides Business Update

Onboarding of commercial field force ongoing and to be fully completed by the end of April, 2022 MONTREAL, April 13, 2022 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (Theratechnologies, or Company) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical...

Apr 08, 2022 01:00 pm ET

Theratechnologies Presents New In Vivo TH1902 Preclinical Data Demonstrating Tumor Growth Inhibition of Human Cancer Stem-Like Cells (CD133+) in Both Triple-Negative Breast and Ovarian Cancers AACR An

Theratechnologies Inc. (“Theratechnologies” or “the Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced the Company’s participation in three...

Mar 31, 2022 05:05 pm ET

Theratechnologies to Announce Financial Results for Its First Quarter 2022

Theratechnologies Inc. (TSX: TH) (NASDAQ: THTX) (Theratechnologies), a biopharmaceutical company focused on the development and commercialization of innovative therapies, announced today that it will report financial results for its first quarter...

Mar 08, 2022 04:31 pm ET

Theratechnologies to Present Three Posters at AACR Including New In Vivo TH1902 Preclinical Data Demonstrating Tumor Growth Inhibition of Human Cancer Stem-Like Cells (CD133+) in Both Triple-Negative

Theratechnologies Inc. (“Theratechnologies” or “the Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that three poster abstracts have been...

Feb 24, 2022 07:30 am ET

Theratechnologies Reports Financial Results for Fiscal 2021 and Provides Business Update

Company announces revenue guidance of US$79M to US$84M for Fiscal 2022 MONTREAL, Feb. 24, 2022 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (Theratechnologies, or Company) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the...

Feb 16, 2022 07:30 am ET

Theratechnologies Presents Results From Trogarzo® IV Push Administration Study at CROI 2022

Feb 15, 2022 07:30 am ET

Theratechnologies Strengthens Global Commercial Capabilities by Launching Internal Field Force

Theratechnologies Inc. (“Theratechnologies” or “the Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced the strengthening of its global commercial...

Feb 10, 2022 07:00 am ET

Theratechnologies to Announce Financial Results for Its Fourth Quarter and Full Fiscal Year 2021

Theratechnologies Inc. (TSX: TH) (NASDAQ: THTX) (Theratechnologies), a biopharmaceutical company focused on the development and commercialization of innovative therapies, announced today that it will report financial results for its fourth quarter...

Dec 06, 2021 11:52 am ET

Theratechnologies Submits Supplemental Biologics License Application to FDA Advancing Development of IV Push Trogarzo® for Patients Living With HIV

Theratechnologies Inc. (Theratechnologies or Company) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, is pleased to announce the submission of a supplemental biologics...

Nov 26, 2021 01:06 pm ET

Theratechnologies Named Recipient of the 2021 ADRIQ Innovation Award in the "Life Sciences" Category

Theratechnologies Inc. (Theratechnologies, or Company) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, is pleased to announce that it was awarded of the 2021 Innovation...

Nov 23, 2021 08:46 am ET

Theratechnologies Announces Renewal of Shelf Prospectus and Registration Statement; At-The-Market Facility to be Extended

Nov 23, 2021 08:46 am ET

Theratechnologies Announces Renewal of Shelf Prospectus and Registration Statement; At-The-Market Facility to be Extended

Nov 03, 2021 07:30 am ET

Theratechnologies to Present at the Credit Suisse 30th Annual Healthcare Conference on November 11, 2021

Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that Paul Levesque, President and Chief Executive Officer,...

Oct 26, 2021 02:00 am ET

Theratechnologies Announces Reimbursement Agreement in Italy for Trogarzo® for Eligible Patients With Multi-Drug Resistant HIV-1

Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, is pleased to announce that it has reached an agreement with the Italian...

Oct 22, 2021 09:15 am ET

Theratechnologies Announces Publication in Frontiers in Oncology Journal Highlighting SORT1+ Technology™ for Targeting SORT1-Mediated Vasculogenic Mimicry

Oct 13, 2021 07:00 am ET

Theratechnologies Reports Financial Results for the Third Quarter of Fiscal 2021 and Provides Business Update

Theratechnologies Inc. (Theratechnologies, or Company) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today reported business highlights and financial results for its...

Oct 06, 2021 08:30 am ET

Theratechnologies to Present at the H.C. Wainwright 5th Annual Nash Investor Conference

Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that Christian Marsolais, Ph.D., Senior Vice President and...

Sep 29, 2021 08:30 am ET

Theratechnologies to Announce Financial Results for Its Third Quarter Fiscal 2021

Theratechnologies Inc. (TSX: TH) (NASDAQ: THTX) (Theratechnologies), a biopharmaceutical company focused on the development and commercialization of innovative therapies, announced today that it will report financial results for its third quarter...

Sep 22, 2021 08:08 am ET

Theratechnologies Announces Positive Results for Trogarzo® IV Push Administration Study

Sep 16, 2021 09:02 am ET

Theratechnologies to Present at the Cantor Fitzgerald Global Healthcare Conference on September 29, 2021

Aug 13, 2021 09:08 am ET

Theratechnologies Announces Publication of TH1902 Preclinical Data in Peer-Reviewed Journal, Cancer Science

Theratechnologies, Inc. (Theratechnologies, or Company) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, announced today the publication of data from its preclinical...

Aug 04, 2021 08:00 am ET

Theratechnologies to Present at the Canaccord Genuity 41st Annual Growth Conference

Jul 23, 2021 07:30 pm ET

Theratechnologies Establishes New At-The-Market Facility

MONTREAL, July 23, 2021 /CNW Telbec/ - Theratechnologies Inc. ("Theratechnologies" or the "Company") (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it has established an at-the-market ("ATM") equity program allowing Theratechnologies to issue and sell up to US $50 million common shares from treasury (the "Common Shares") to the public at the Company's sole discretion and at the prevailing market price. Sales of the Common Shares under the ATM program will be made pursuant to the terms o

Jul 15, 2021 07:00 am ET

Theratechnologies Reports Financial Results for the Second Quarter of Fiscal 2021 and Provides Update on Its Planned Phase 3 Clinical Trial in NASH

Theratechnologies, Inc. (Theratechnologies, or Company) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today reported financial results for the second quarter ended...

Jun 30, 2021 11:28 am ET

CORRECTION: Theratechnologies to Announce Financial Results for Its Second Quarter Fiscal 2021

In a release issued this morning, Wednesday, June 30, 2021, under the same headline, by Theratechnologies Inc. (TSX: TH) (NASDAQ: THTX), please note that in the last sentence of the first paragraph, the date should be Thursday, July 15, 2021, not...

Jun 30, 2021 07:30 am ET

Theratechnologies to Announce Financial Results for Its Second Quarter Fiscal 2021

Theratechnologies Inc. (TSX: TH) (NASDAQ: THTX) (Theratechnologies), a biopharmaceutical company focused on the development and commercialization of innovative therapies announced today that it will report its financial results for the second...

Jun 23, 2021 07:30 am ET

Theratechnologies Appoints New Board Member

Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced the appointment of Mr. Frank Holler as a new independent...

Jun 21, 2021 09:00 am ET

Theratechnologies Announces New Preclinical Findings for Its Lead Investigational Peptide-Drug Conjugate TH1902 for the Potential Treatment of Metastatic Cancers

Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced new preclinical in vivo findings on the anti-metastatic...

Jun 10, 2021 04:01 pm ET

Theratechnologies to Host Key Opinion Leader Event to Discuss its SORT1+ Technology™ for the Treatment of All Sortilin-Expressing Cancers

Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it will host a key opinion leader (KOL) webinar on the...

May 31, 2021 08:00 am ET

Theratechnologies Hires Vice President, Human Resources

Theratechnologies Inc. (Theratechnologies, or the Company (TSX: TH) (NASDAQ: THTX)), a biopharmaceutical company focused on the development and commercialization of innovative therapies, is pleased to announce that Mr. André Dupras is joining the...

May 20, 2021 07:30 am ET

Theratechnologies Announces Results From Two Posters Presented at ACTHIV 2021 Annual Meeting Highlighting Positive Patient Experience With Trogarzo®

Theratechnologies Inc. (Theratechnologies, or Company) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today reported on positive results presented in two separate...

May 18, 2021 09:24 am ET

Theratechnologies to Participate in Virtual Fireside Chat With Canaccord Genuity on May 20, 2021

May 13, 2021 11:15 am ET

Announcements in Conjunction With Theratechnologies Annual Meeting

Theratechnologies Inc. (Theratechnologies, or Company) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today held its annual meeting of shareholders. As part of the...

Apr 14, 2021 07:30 am ET

Theratechnologies Reports First Quarter 2021 Financial Results and Recent Business Highlights

Theratechnologies Inc. (Theratechnologies, or Company) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today reported business highlights and financial results for the...

Apr 12, 2021 04:30 pm ET

Theratechnologies to Present at the Bloom Burton & Co. Healthcare Investor Conference

Apr 12, 2021 01:46 pm ET

Theratechnologies to Announce Financial Results for Its First Quarter Fiscal 2021

Theratechnologies Inc. (TSX: TH) (NASDAQ: THTX) (Theratechnologies), a biopharmaceutical company focused on the development and commercialization of innovative therapies announced today that it will report its financial results for the first...

Apr 10, 2021 10:02 am ET

Theratechnologies Presents New In Vivo Pre-Clinical Data at AACR Demonstrating Significant Anti-Tumor Activity of TH1902 in All Studied Cancer Types

Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that new in vivo preclinical data were presented at the 2021...

Mar 29, 2021 01:00 pm ET

Theratechnologies Announces Two Strategic Hires to Support its Commercial and Pipeline Assets

Theratechnologies Inc. (Theratechnologies, or the Company (on a consolidated basis)) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, is pleased to announce the addition...

Mar 24, 2021 07:30 am ET

Theratechnologies Announces First Patient Dosed in Phase 1 Clinical Trial of TH1902 for Sortilin Positive Solid Tumors

Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, is pleased to announce that the first patient received a dose of TH1902, its...

Mar 20, 2021 11:00 am ET

Theratechnologies Announces New Data Demonstrating Tesamorelin’s Positive Effect on Immune Response Linked to Liver Inflammation

Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, is pleased to announce that new data, demonstrating the positive effect of...

Mar 10, 2021 04:30 pm ET

Theratechnologies Announces Two E-Posters on TH1902 To Be Presented at American Association for Cancer Research (AACR) Annual Meeting 2021

Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, is pleased to announce that new positive pre-clinical data on TH1902, its...

Feb 25, 2021 04:43 pm ET

Theratechnologies to Present at the H.C. Wainwright Global Life Sciences Conference

Feb 25, 2021 07:30 am ET

Theratechnologies Announces Fourth Quarter and Fiscal Year 2020 Financial Results

Theratechnologies Inc. (Theratechnologies, or Company) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced its financial results for the fourth quarter and...

Feb 11, 2021 10:21 am ET

Theratechnologies to Announce Financial Results for Fourth Quarter and Fiscal Year 2020

Theratechnologies Inc. (TSX: TH) (NASDAQ: THTX) (Theratechnologies), a biopharmaceutical company focused on the development and commercialization of innovative therapies announced, today that it will issue its financial results for the fourth...

Feb 04, 2021 07:30 am ET

Theratechnologies’ Lead Peptide Drug Conjugate TH1902 Receives FDA Fast Track Designation for the Treatment of Sortilin-expressing Cancers

Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, is pleased to announce that the United States Food and Drug Administration...

Jan 19, 2021 09:41 am ET

Theratechnologies Announces Closing of US$46 Million Bought-Deal Public Offering, Including Full Exercise of the Over-Allotment Option

Jan 19, 2021 09:40 am ET

Theratechnologies Announces Closing of US$46 Million Bought-Deal Public Offering, Including Full Exercise of the Over-Allotment Option

Jan 14, 2021 09:49 am ET

Theratechnologies to Present at the B. Riley Securities Virtual Oncology Investor Conference

Jan 11, 2021 08:19 pm ET

Theratechnologies Announces US$40 Million Bought-deal Public Offering of Units

Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX) ), a biopharmaceutical company focused on the development and commercialization of innovative therapies, is pleased to announce that it has entered into an...

Jan 11, 2021 07:13 pm ET

Theratechnologies Announces US$40 Million Bought-Deal Public Offering of Units

Jan 07, 2021 07:00 am ET

Theratechnologies Announces Preliminary Fourth Quarter and Full Fiscal Year 2020 Revenues and Provides Update on R&D Activities

Dec 08, 2020 07:00 am ET

Theratechnologies Announces New Findings for its Lead Investigational Compound TH1902 for the Treatment of Several Additional Cancers

Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced new pre-clinical in vivo findings regarding the efficacy and...

Nov 23, 2020 04:01 pm ET

Theratechnologies to Present at the Piper Sandler Virtual Healthcare Conference

Nov 16, 2020 10:30 am ET

Theratechnologies Announces Data From Oral Presentation at AASLD Showing How Tesamorelin Can Reduce Fibrosis and NASH

Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today highlighted new data on the mechanism of effect of tesamorelin...

Nov 06, 2020 01:35 pm ET

Theratechnologies Announces that Data on the Mechanism of Effect of Tesamorelin in NAFLD will be Presented at The Liver Meeting® 2020

Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that an oral presentation including data on the mechanism of...

Nov 03, 2020 04:01 pm ET

Theratechnologies Announces Departure of Chief Commercial Officer

Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that Jovan Antunovic, Senior Vice President and Chief...

Oct 22, 2020 04:09 pm ET

Theratechnologies to Present at Upcoming Investor Conferences on October 29 and November 10, 2020

Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that management will be presenting at the following upcoming...

Oct 16, 2020 07:30 am ET

Theratechnologies Appoints Two New Board Members

Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced the appointment of Mr. Andrew Molson and Mr. Alain Trudeau as...

Oct 15, 2020 07:00 am ET

Theratechnologies Announces Financial Results for the Third Quarter of Fiscal 2020

Theratechnologies Inc. (Theratechnologies, or Company) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced its financial results for the third quarter of...

Oct 13, 2020 04:37 pm ET

Theratechnologies Confirms Issuance of U.S. Patent Covering the Use of Tesamorelin in the Treatment of Individuals Suffering From NAFLD/NASH

Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, is pleased to announce that the United States Patent and Trademark Office...

Oct 05, 2020 04:01 pm ET

Theratechnologies to Announce Financial Results for Third Quarter 2020

Theratechnologies Inc. (TSX: TH) (NASDAQ: THTX) (Theratechnologies) announced today that it will issue its financial results for the third quarter ended August 31, 2020 on Thursday, October 15, 2020. A conference call will be held on October 15,...

Sep 30, 2020 04:01 pm ET

Theratechnologies to Present at the H.C. Wainwright 4th Annual NASH Investor Conference on October 5

Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that Dr. Christian Marsolais, Senior Vice President and Chief...

Sep 21, 2020 07:30 am ET

Theratechnologies Announces Preliminary Third-Quarter Fiscal 2020 Financial Results

Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced select preliminary financial results for the third quarter...

Sep 10, 2020 07:30 am ET

Theratechnologies to Develop Tesamorelin for the Treatment of NASH in the General Population

Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, is pleased to announce that it plans to pursue Phase 3 clinical development...

Sep 10, 2020 02:00 am ET

Theratechnologies Announces Launch of Trogarzo® in Germany

Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, is pleased to announce that Trogarzo® will be commercially available in...

Jul 30, 2020 07:30 am ET

Theratechnologies to Present at the Canaccord Genuity 40th Annual Growth Conference on August 12, 2020

Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a commercial-stage biopharmaceutical company, today announced that Philippe Dubuc, the Senior Vice President and Chief Financial Officer of Theratechnologies, will present at the...

Jul 23, 2020 04:01 pm ET

Theratechnologies Reports That Tesamorelin Improves Liver Health

Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a commercial-stage biopharmaceutical company, is pleased to announce new data that further support the potential role of tesamorelin in the treatment of HIV-associated...

Jul 16, 2020 12:23 pm ET

Announcements in Conjunction With Theratechnologies Annual Meeting

Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a commercial-stage biopharmaceutical company, today held its annual meeting of shareholders. As part of the meeting, shareholders proceeded to elect the below candidates to the...

Jul 15, 2020 07:30 am ET

Theratechnologies Announces Financial Results for the Second Quarter of Fiscal 2020

Theratechnologies Inc. (Theratechnologies, or Company) (TSX: TH) (NASDAQ: THTX), a commercial-stage biopharmaceutical company, today announced its financial results for the second quarter of fiscal 2020 ended May 31, 2020. “While the COVID-19...

Jul 07, 2020 07:30 am ET

Theratechnologies Confirms Bioequivalence of New Tesamorelin Formulation

Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a commercial-stage biopharmaceutical company, is pleased to announce that it has successfully completed a bioequivalence study evaluating a new formulation of tesamorelin compared...

Jul 06, 2020 07:30 am ET

Theratechnologies Announces Ibalizumab Inhibits HIV-2 In Vitro

Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a commercial-stage biopharmaceutical company, is pleased to announce that data presented at the 23rd International AIDS Conference virtual meeting, demonstrates that ibalizumab is...

Jun 22, 2020 07:30 am ET

New Data Show Theratechnologies’ SORT1+ Technology is Effective in Many Treatment-Resistant Cancers

Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a commercial-stage biopharmaceutical company, is pleased to announce that new data featuring its investigational sortilin 1 (SORT1)-targeting peptide-drug conjugate technology...

May 15, 2020 07:30 am ET

Theratechnologies Unveils New Positive Data for Its Investigational Peptide-Drug Conjugates Targeting Sortilin Positive Cancers

Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a commercial-stage biopharmaceutical company, today announced new positive results for its investigational Sortilin (SORT1) targeting peptide-drug conjugates (PDCs) which will be...

May 12, 2020 07:30 am ET

Theratechnologies to Present at the RBC Capital Markets Global Healthcare Conference on May 19, 2020

Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a commercial-stage biopharmaceutical company, today announced that management will present at the RBC Global Healthcare Conference on Tuesday, May 19, 2020 at 9:10 a.m. ET. The...

Apr 27, 2020 07:30 am ET

Theratechnologies Announces New Positive Results for two Investigational Peptide-Drug Conjugates Targeting Sortilin Positive Ovarian Cancer

Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a commercial-stage biopharmaceutical company, today announced that new positive results about its two investigational peptide-drug conjugates (PDC) TH1902 and TH1904 will be...

Apr 16, 2020 03:23 pm ET

Theratechnologies to Make Oral Presentation on Oncology Platform During AACR Virtual Annual Meeting

Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a commercial-stage biopharmaceutical company, today announced that it will make an oral presentation on new results from its sortilin targeting oncology platform during a virtual...

Apr 16, 2020 07:30 am ET

Theratechnologies Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Theratechnologies Inc., or Theratechnologies (TSX: TH) (NASDAQ: THTX), a commercial-stage biopharmaceutical company, announced today that Paul Lévesque, the current President and Chief Executive Officer of Theratechnologies, was granted 487,421...

Apr 14, 2020 07:30 am ET

Theratechnologies Announces Financial Results for the First Quarter of 2020

Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a commercial-stage biopharmaceutical company, today announced its financial results for the first quarter ended February 29, 2020. First quarter 2020 financial highlights First...

Mar 31, 2020 07:30 am ET

THERATECHNOLOGIES PROVIDES BUSINESS UPDATE RELATED TO CURRENT COVID-19 SITUATION

Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a commercial-stage biopharmaceutical company, today issued an update on the Company’s activities in relation to the current worldwide COVID-19 pandemic. “Theratechnologies’...

Mar 11, 2020 12:00 pm ET

Visceral Fat is a Predictor of Liver Fibrosis and Fibrosis Progression in People Living With HIV

Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a commercial-stage biopharmaceutical company, is pleased to announce that Dr. Lindsay Fourman, from Harvard Medical School, presented data demonstrating that visceral fat is a...

Mar 02, 2020 07:00 am ET

Change to Theratechnologies Management

Paul Lévesque will be appointed as President and CEO, replacing Luc Tanguay, who is retiring

Feb 25, 2020 07:30 am ET

Theratechnologies Announces Financial Results for Fiscal Year 2019

Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a commercial-stage biopharmaceutical company, today announced its financial results for the year ended November 30, 2019. Fiscal Year 2019 Financial Highlights Record revenue...

Feb 18, 2020 08:00 am ET

Theratechnologies to Announce Financial Results for Fourth Quarter and Fiscal Year 2019

Theratechnologies Inc. (TSX: TH) (Theratechnologies) announced today that it will issue its financial results for the fourth quarter and fiscal year ended November 30, 2019, on Tuesday, February 25, 2020. A conference call will be held on...

Feb 04, 2020 07:30 am ET

Theratechnologies Signs Agreements With Massachusetts General Hospital and Dr. Steven Grinspoon

Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a commercial-stage biopharmaceutical company, is pleased to announce the signing of long-term agreements with the Massachusetts General Hospital (MGH) and Dr. Steven Grinspoon...

Dec 19, 2019 09:06 am ET

Theratechnologies Issues Preliminary Revenue Estimates for Fiscal Year 2019 and Revenue Guidance for Fiscal Year 2020

Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a commercial-stage biopharmaceutical company, today provided preliminary revenue estimates for its recently completed fiscal year 2019 and revenue guidance for fiscal year 2020....

Dec 13, 2019 07:30 am ET

Theratechnologies’ Oncology Platform Improves Efficacy and Tolerability of Docetaxel in Vivo and in Vitro

Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a commercial-stage biopharmaceutical company, is pleased to report on new data presented today at the San Antonio Breast Cancer Symposium (SABCS). Results from in vitro and in...

Nov 27, 2019 10:59 am ET

Theratechnologies’ CFO to Attend Piper Jaffray 31st Annual Healthcare Conference in New York City

Theratechnologies Inc. (Theratechnologies) (TSX: TH) is pleased to announce that Philippe Dubuc, Senior Vice President and Chief Financial Officer will attend the 31st Annual Healthcare Conference starting at 12:30 p.m. on December 3rd, 2019 at the...

Nov 25, 2019 07:30 am ET

Theratechnologies Starts Commercialization of New EGRIFTA SVᵀᴹ in the United States

Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a commercial-stage biopharmaceutical company, is pleased to announce that EGRIFTA SVᵀᴹ (2mg/vial) is now commercially available in the United States. Our salesforce has started...

Nov 14, 2019 03:28 pm ET

Theratechnologies’ CFO to Attend Stifel Healthcare Conference in New York City

Theratechnologies Inc. (Theratechnologies) (TSX: TH), a commercial-stage biopharmaceutical company, is pleased to announce that Philippe Dubuc, Senior Vice President and Chief Financial Officer, will attend the Stifel Healthcare Conference which...

Nov 07, 2019 07:30 am ET

Trogarzo® Remains Effective Close to a Decade After Treatment Initiation

Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a commercial-stage biopharmaceutical company, is pleased to announce that data presented at the 17th European AIDS Conference, currently being held in Basel, Switzerland,...

Oct 21, 2019 07:30 am ET

Theratechnologies Provides Details About R&D Day Webcast

Theratechnologies Inc. (“Theratechnologies” or the “Company”) (NASDAQ: THTX) (TSX: TH), a commercial-stage pharmaceutical company addressing unmet medical needs for people with orphan medical conditions, including those living with HIV, is pleased...

Oct 14, 2019 10:49 am ET

REMINDER - Tesamorelin Study Results on NAFLD Published in Lancet HIV

Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX) is pleased to announce that results from a recent trial conducted at the Massachusetts General Hospital and the National Institute of Allergy and Infectious Diseases, part of the...

Oct 11, 2019 06:30 pm ET

Tesamorelin Study Results on NAFLD Published in Lancet HIV

Oct 10, 2019 07:30 am ET

Canadian Commercial-Stage Biopharmaceutical Company Theratechnologies Announces NASDAQ Listing

Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH), a commercial-stage biopharmaceutical company addressing unmet medical needs for people with orphan medical conditions, including those living with HIV, is pleased to announce...

Oct 08, 2019 07:30 am ET

Theratechnologies Announces Financial Results for the Third Quarter of 2019

Theratechnologies Inc. (Theratechnologies) (TSX: TH) today announced its financial results for the third quarter ended August 31, 2019. Third quarter 2019 financial highlights • Third quarter net sales of $16,111,000, up 19.3% from the same...

Oct 04, 2019 01:00 pm ET

1.7 Million Dollars Grant Towards Development of Theratechnologies’ Targeted Oncology

Theratechnologies Inc. (Theratechnologies) (TSX: TH) is pleased to announce that the Canadian Cancer Society and the Government of Quebec, through the Consortium Québécois sur la découverte du médicament (CQDM), will contribute to a grant totaling...

Oct 03, 2019 08:17 am ET

New 48-Week Data Presented at IDWeek Show Trogarzo® Remains Safe and Effective

Theratechnologies Inc. (Theratechnologies) (TSX: TH) is pleased to announce that new 48-week data from the TMB-311 extension study confirm that Trogarzo® provides durable viral suppression and a safety profile consistent with the 24-week pivotal...

Oct 01, 2019 02:14 pm ET

Theratechnologies to Announce Financial Results for Third Quarter 2019

Theratechnologies Inc. (TSX: TH) (Theratechnologies) announced today that it will issue its financial results for the third quarter ended August 31, 2019, on Tuesday, October 8, 2019. A conference call will be held on October 8, 2019 at 8:30 a.m....

Sep 30, 2019 12:18 pm ET

Theratechnologies to Present at Cantor Fitzgerald Global Healthcare Conference in New York City

Theratechnologies Inc. (Theratechnologies) (TSX: TH) is pleased to announce that Philippe Dubuc, Senior Vice President and Chief Financial Officer will make a presentation at the 2019 Cantor Fitzgerald Global Healthcare Conference on October 2,...

Sep 26, 2019 02:13 pm ET

European Commission Approves Trogarzo®

Theratechnologies Inc. (Theratechnologies) (TSX: TH) is pleased to announce that Trogarzo® (ibalizumab) was approved today by the European Commission. “The approval of Trogarzo® by the European Commission represents a historical milestone for...

Sep 26, 2019 10:29 am ET

Theratechnologies Included in the First TSX30 Ranking

Theratechnologies Inc. (Theratechnologies) (TSX: TH) is pleased to announce that it ranked 21st on the first TSX30 ranking of top performers on the Toronto Stock Exchange. The ranking was established based on the following criteria: Corporate...

Sep 26, 2019 09:00 am ET

Toronto Stock Exchange Introduces the TSX30

Canada's premier equities marketplace launches new program to showcase top performing companies, TSX to host market open ceremony September 27

Sep 19, 2019 07:30 am ET

Theratechnologies Reaches Agreement With AIDS Drug Assistance Program (ADAP) for New EGRIFTA SV™

Theratechnologies Inc. (TSX: TH) is pleased to announce that an agreement has been reached with the AIDS Drug Assistance Program Crisis Task Force for EGRIFTA SVTM (tesamorelin for injection), which will commercially launch in the United States...

Sep 12, 2019 09:01 am ET

Theratechnologies Ranks Among Canada’s 500 Fastest Growing Companies

Theratechnologies Inc. (Theratechnologies) (TSX: TH) is pleased to announce that it has been recognized as 137th fastest growing Canadian companies over the last five years according to the 2019 Growth 500 ranking released today by Canadian...

Aug 12, 2019 07:30 am ET

Theratechnologies Files Application to List on NASDAQ

Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) today announced that it has applied to list its common shares on NASDAQ. “We believe that being listed on NASDAQ will help to foster interest from more potential investors...

Aug 08, 2019 04:31 pm ET

Theratechnologies Regains Control Over Distribution Rights to EGRIFTA® Worldwide

Theratechnologies Inc. (Theratechnologies) (TSX: TH) is pleased to announce that it has regained complete control over distribution rights of EGRIFTA® worldwide, following the termination of agreements with commercial partners in various...

Aug 07, 2019 04:30 pm ET

Jean-Denis Talon Retires From Theratechnologies’ Board of Directors

Theratechnologies Inc. (Theratechnologies) (TSX: TH) today announced that Mr. Jean-Denis Talon has decided to retire from the board of directors of Theratechnologies. He was first elected on the board of directors in 2001. “I feel honored and...

Aug 05, 2019 07:30 am ET

Theratechnologies’ CFO to Attend 39ᵗʰ Annual Growth Conference Held by Canaccord Genuity in Boston

Theratechnologies Inc. (Theratechnologies) (TSX: TH) is pleased to announce that Philippe Dubuc, Senior Vice President and Chief Financial Officer, will attend the 39th Annual Growth Conference held by Canaccord Genuity in Boston, Massachusetts,...

Jul 26, 2019 07:50 am ET

Theratechnologies Receives Positive Recommendation From the CHMP for Trogarzo® in the European Union

Theratechnologies Inc. (Theratechnologies) (TSX: TH) is pleased to announce that the Committee for Medicinal Products for Human use (CHMP) in Europe has given a positive recommendation for the approval of Trogarzo® (ibalizumab) for the treatment of...

Ad blocking detected

Theratechnologies Inc. (T:TH)

Business Focus: Biopharmaceuticals